ALS LIMITED (ALQ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALQ - ALS LIMITED

Year End: March
GICS Industry Group : Commercial & Professional Services
Debt/EBITDA: 2.41
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

ALS Ltd provides laboratory and testing services across the mining, industrial and life sciences sector. It operates in over 65 countries. Formerly Campbell Brothers Ltd it first listed in 1952 and changed name to ALS in 2012.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$13.13

16 Apr
2024

-0.160

OPEN

$13.20

-1.20%

HIGH

$13.29

845,525

LOW

$13.04

TARGET
$12.45 -5.2% downside
Franking for last dividend paid out: 20%
OTHER COMPANIES IN THE SAME SECTOR
AVD . BSA . CG1 . CLG . CVL . CWY . CXL . DOW . DUR . EGN . EVS . FLC . IPG . LBL . MAD . PPK . SDV . SHA . SND . SSM . VEE .
FNARENA'S MARKET CONSENSUS FORECASTS
ALQ: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 64.7 xxx
DPS (cps) xxx N/A 38.9 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 20.3 xxx
Dividend Yield xxx N/A 3.0% xxx
Div Pay Ratio(%) xxx N/A 60.2% xxx

Dividend yield today if purchased 3 years ago: 3.92%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

3.02

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 23/11 - ex-div 19.6c (franking 20%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx57.7
DPS All xxxxxxxxxxxxxxx39.7
Sales/Revenue xxxxxxxxxxxxxxx2,279.2 M
Book Value Per Share xxxxxxxxxxxxxxx282.4
Net Operating Cash Flow xxxxxxxxxxxxxxx443.5 M
Net Profit Margin xxxxxxxxxxxxxxx12.07 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx22.11 %
Return on Invested Capital xxxxxxxxxxxxxxx11.83 %
Return on Assets xxxxxxxxxxxxxxx8.81 %
Return on Equity xxxxxxxxxxxxxxx22.11 %
Return on Total Capital xxxxxxxxxxxxxxx17.30 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx120.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx180 M
Long Term Debt xxxxxxxxxxxxxxx1,269 M
Total Debt xxxxxxxxxxxxxxx1,448 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx180 M
Price To Book Value xxxxxxxxxxxxxxx4.38

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx146.1 M
Capex % of Sales xxxxxxxxxxxxxxx6.41 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,451 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx379 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx302 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

28/03/2024

3

Neutral

$13.30

1.29%

ALS Ltd is set to expand its life sciences footprint in the US and Europe with the acquisitions of York Analytical Laboratories and Wessling Holding. The -$225m acquisitions will be funded through existing debt facilities.

The former will see ALS Ltd increase exposure to the North American PFAS testing market, while the latter expands geographic reach in Germany, France and Switzerland.

As per UBS, the acquisitions align with the company's target to emphasise life sciences growth, but the broker does expect the purchase will weigh on margins in the short term.

The Neutral rating and target price of $13.30 are retained.

FORECAST
UBS forecasts a full year FY24 EPS of 65.00 cents.
UBS forecasts a full year FY25 EPS of 66.00 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

ALQ STOCK CHART